Drugs / claudin18.2 CAR-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07266311 | Dec 2025 → Dec 2035 expected | — | Chengdu Ucello Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05472857 | Aug 2022 → Dec 2024 | gastric cancer, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm, ovarian carcinoma | Suzhou Immunofoco Biotechnology Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Claudin 18.2 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05472857 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T-cell therapy” NCT05472857 ↗ |
| Route | Other | “anti-claudin18.2 chimeric antigen receptor T-cell infusion” NCT05472857 ↗ |
| Target | CLDN18 | “CLDN18.2-targeting CAR T Cells” NCT05472857 ↗ |